Home Blog of Signal Transduction Protein Tyrosine Kinase c-Met

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

c-Met

A portable photoacoustic device for facile and sensitive detection of serum alkaline phosphatase activity

66 views | Feb 07 2024

The development of a portable photoacoustic device utilizing silver nanoparticles as a signal probe for alkaline phosphatase detection in serum, exhibiting excellent sensitivity, reproducibility, and practical application potential, marks a significant stride in bioassay innovation. [Read the Full Post]

Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

112 views | Jan 15 2024

XL092, a multi-receptor tyrosine kinase inhibitor, exhibits potent antitumor effects and immunomodulatory properties in preclinical models, supporting its potential for clinical evaluation, particularly in combination with immune checkpoint inhibitors. [Read the Full Post]

Polypharmacologic Reprogramming of Tumor-Associated Macrophages toward an Inflammatory Phenotype

101 views | Jan 11 2024

This study's establishment of a physiologically relevant in vitro system for TAM polarization unveils BMS-794833 as a potent inhibitor, independent of primary targets but reliant on multiple signaling pathways, offering a promising strategy to reprogram TAMs and suppress cancer growth. [Read the Full Post]

Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer

114 views | Dec 27 2023

The identification of c-Met phosphorylation as a pivotal mechanism driving radioresistance-associated aggressiveness in HNSCC cells offers a promising therapeutic strategy by targeting this pathway with inhibitors like SU11274 to enhance the efficacy of radiotherapy. [Read the Full Post]

E7050 Suppresses the Growth of Multidrug-Resistant Human Uterine Sarcoma by Inhibiting Angiogenesis via Targeting of VEGFR2-Mediated Signaling Pathways

85 views | Dec 24 2023

E7050 demonstrates potent anti-tumor and anti-angiogenic effects by inhibiting VEGFR2 phosphorylation and downstream signaling pathways in endothelial cells, reducing neovessel formation in vitro and in vivo, and attenuating tumor growth and angiogenesis in a xenograft model, suggesting its promising potential as a therapeutic agent for cancer and angiogenesis-related disorders. [Read the Full Post]

Inhibition of Mertk Signaling Enhances Bone Healing after Tooth Extraction

91 views | Nov 29 2023

Targeting Mertk, a specific TAM receptor, enhances bone regeneration after tooth extraction, offering a potential therapeutic approach for improving outcomes in cases where the regenerative process is impaired. [Read the Full Post]

Autocrine EGF and TGF-α promote primary and acquired resistance to ALK/c-Met kinase inhibitors in non-small-cell lung cancer

43 views | Nov 29 2023

Increased autocrine production of EGF and TGF-α mediates both primary and acquired resistance to ALK and c-MET inhibitors in non-small-cell lung cancer, suggesting a potential therapeutic strategy involving combination treatments with EGFR inhibitors. [Read the Full Post]

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

0 views | Nov 01 2023

The study demonstrated that the combination of the MET inhibitor merestinib with the FGFR inhibitor LY2874455 showed preliminary safety and biological activity, indicating the potential of targeting MET and FGFR pathways in the treatment of relapsed/refractory acute myeloid leukemia. [Read the Full Post]

Assessment of alterations in histone modification function and guidance for death risk prediction in cervical cancer patients

0 views | Oct 30 2023

The study comprehensively evaluated histone modification status in cervical cancer patients, identifying a novel HMAG signature of nine histone modification-associated genes with strong prognostic value, offering crucial insights into prognosis prediction and tailored clinical treatments. [Read the Full Post]

The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis

67 views | Oct 27 2023

The meta-analysis findings suggest that tivantinib does not appear to confer a significant benefit for the treatment of MET-high hepatocellular carcinoma, and it is associated with an increased risk of grade ≥3 neutropenia and leukopenia. [Read the Full Post]